Drugs / T517
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04891237 | Jun 2021 → Jan 2026 overdue | allergic asthma, allergic rhinitis | Inmunotek S.L. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T517 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04891237 ↗ |
| Modality | Protein / enzyme biologic | “Purified and polymerized with glutaraldehyde allergen extract” NCT04891237 ↗ |
| Route | Subcutaneous | “subcutaneous immunotherapy” NCT04891237 ↗ |